KOSDAQ - Delayed Quote KRW

BIFIDO Co., Ltd. (238200.KQ)

Compare
3,025.00
+25.00
+(0.83%)
At close: 3:30:30 PM GMT+9
Loading Chart for 238200.KQ
  • Previous Close 3,000.00
  • Open 3,000.00
  • Bid 2,950.00 x --
  • Ask 3,025.00 x --
  • Day's Range 2,950.00 - 3,045.00
  • 52 Week Range 2,750.00 - 5,800.00
  • Volume 3,954
  • Avg. Volume 5,949
  • Market Cap (intraday) 24.744B
  • Beta (5Y Monthly) 1.01
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BIFIDO Co., Ltd. produces probiotics-based products in South Korea and internationally. It offers bifidobacterium strain products, such as BGN4 for immune modulating; BORI used to treat rotavirus infection in infants; and AD011 for general intestinal health problems. The company was founded in 1999 and is headquartered in Hongcheon-eup, South Korea.

www.bifido.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 238200.KQ

View More

Performance Overview: 238200.KQ

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

238200.KQ
2.72%
KOSPI Composite Index (^KS11)
2.75%

1-Year Return

238200.KQ
44.50%
KOSPI Composite Index (^KS11)
10.09%

3-Year Return

238200.KQ
67.92%
KOSPI Composite Index (^KS11)
10.61%

5-Year Return

238200.KQ
65.03%
KOSPI Composite Index (^KS11)
42.89%

Compare To: 238200.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 238200.KQ

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    24.54B

  • Enterprise Value

    33.74B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.99

  • Price/Book (mrq)

    0.53

  • Enterprise Value/Revenue

    2.73

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.31%

  • Return on Assets (ttm)

    -0.78%

  • Return on Equity (ttm)

    0.47%

  • Revenue (ttm)

    18.48B

  • Net Income Avi to Common (ttm)

    242.14M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    14.07B

  • Total Debt/Equity (mrq)

    23.43%

  • Levered Free Cash Flow (ttm)

    -15.34B

Research Analysis: 238200.KQ

View More

Company Insights: 238200.KQ

Research Reports: 238200.KQ

View More

People Also Watch